Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
Vera Therapeutics (Nasdaq: VERA) announced that data from the Phase 3 ORIGIN trial of atacicept in IgA nephropathy (IgAN) will be presented as a featured late-breaking oral presentation in the Opening Plenary at ASN Kidney Week 2025 in Houston.
The oral presentation (Abstract TH-OR083) will be delivered by Richard Lafayette, MD on Thursday, November 6, 2025 from 9:02 AM–9:14 AM CST in Hall A. Two informational posters (INFO12-TH and INFO13-TH) on ORIGIN Extend and PIONEER will be available the same day from 10:00 AM–12:00 PM CST in the Exhibit Hall.
Vera Therapeutics (Nasdaq: VERA) ha annunciato che i dati del trial di fase 3 ORIGIN di atacicept nella nefropatia da IgA (IgAN) verranno presentati come presentazione orale di apertura in evidenza nella Sessione di Apertura alla ASN Kidney Week 2025 a Houston.
La presentazione orale (Abstract TH-OR083) sarà tenuta dal Dr. Richard Lafayette giovedì 6 novembre 2025 dalle 9:02 alle 9:14 CST nella Hall A. Due poster informativi (INFO12-TH e INFO13-TH) su ORIGIN Extend e PIONEER saranno disponibili lo stesso giorno dalle 10:00 alle 12:00 CST nell'Exhibit Hall.
Vera Therapeutics (Nasdaq: VERA) anunció que los datos del ensayo de fase 3 ORIGIN de atacicept en la nefropatía por IgA (IgAN) se presentarán como una presentación oral destacada en la Sesión de Apertura durante la ASN Kidney Week 2025 en Houston.
La presentación oral (Resumen TH-OR083) será dictada por Richard Lafayette, MD el jueves 6 de noviembre de 2025 de 9:02 AM–9:14 AM CST en la Sala A. Dos carteles informativos (INFO12-TH y INFO13-TH) sobre ORIGIN Extend y PIONEER estarán disponibles ese mismo día de 10:00 AM–12:00 PM CST en la Exposición Hall.
Vera Therapeutics (나스닥: VERA)는 atacicept의 IgA 신병증(IgAN)에서의 3상 ORIGIN 시험 데이터가 휴스턴에서 열리는 ASN Kidney Week 2025의 개막 plenary에서 하이라이트 구연으로 발표될 것이라고 발표했다.
구연 발표(초록 TH-OR083)는 Richard Lafayette, MD에 의해 2025년 11월 6일 목요일 오전 9:02–9:14 CST에 Hall A에서 진행된다. ORIGIN Extend와 PIONEER에 관한 두 개의 정보 포스터(INFO12-TH 및 INFO13-TH)도 같은 날 오전 10:00–오전 12:00 CST에 전시관에서 제공된다.
Véra Therapeutics (Nasdaq: VERA) a annoncé que les données de l’essai de phase 3 ORIGIN d’atacicept dans la néphropathie à IgA (IgAN) seront présentées lors d’une présentation orale en ouverture en tant que présentation en vedette lors de la ASN Kidney Week 2025 à Houston.
La présentation orale (Résumé TH-OR083) sera donnée par le Dr Richard Lafayette le jeudi 6 novembre 2025 de 9h02–9h14 CST dans la Halle A. Deux affiches d’information (INFO12-TH et INFO13-TH) sur ORIGIN Extend et PIONEER seront disponibles le même jour de 10h00–12h00 CST dans le Hall d’exposition.
Vera Therapeutics (Nasdaq: VERA) gab bekannt, dass Daten aus der Phase-3-Studie ORIGIN zur atacicept bei IgA-Nephropathie (IgAN) als hervorgehobene späte mündliche Präsentation in der Eröffnungs-Plenarsitzung bei der ASN Kidney Week 2025 in Houston vorgestellt werden.
Die mündliche Präsentation (Abstract TH-OR083) wird von Richard Lafayette, MD am Donnerstag, 6. November 2025 von 9:02–9:14 Uhr CST in Halle A gehalten. Zwei Informationsposter (INFO12-TH und INFO13-TH) zu ORIGIN Extend und PIONEER werden am gleichen Tag von 10:00–12:00 CST im Ausstellungsbereich verfügbar sein.
فيرا للعلاجات (ناسداك: VERA) أعلنت أن بيانات تجربة المرحلة الثالثة ORIGIN لا atacicept في اعتلال الكلى IgA (IgAN) ستُعرض كعرض شفهي بارز في الجلسة الافتتاحية خلال أسبوع كندا Kidney 2025 في هيوستن.
سيُقدَّم العرض الشفهي (الملخص TH-OR083) بواسطة د. Richard Lafayette يوم الخميس 6 نوفمبر 2025 من 9:02 صباحاً–9:14 صباحاً CST في القاعة A. وسيكون هناك جناحين معلوماتيين (INFO12-TH و INFO13-TH) عن ORIGIN Extend وPIONEER متاحين في نفس اليوم من 10:00 صباحاً–12:00 ظهراً CST في قاعة المعرض.
Vera Therapeutics（纳斯达克股票代码：VERA）宣布，ORIGIN试验中 atacicept 在 IgA 肾病（IgAN）上的 III 期数据将作为在 ASN Kidney Week 2025 在休斯顿举行的开幕全体会议中的重点晚场口头报告进行展示。
该口头报告（摘要 TH-OR083）将由 Richard Lafayette, MD 于 2025年11月6日，星期四，从 9:02 AM–9:14 AM CST 在 A厅进行。关于 ORIGIN Extend 和 PIONEER 的两个信息海报（INFO12-TH 和 INFO13-TH）将于同日从 10:00 AM–12:00 PM CST 在展览馆内提供。
- None.
- None.
Insights
Phase 3 ORIGIN will be presented as a late‑breaking oral plenary at ASN Kidney Week on
ORIGIN is a Phase 3 study of atacicept in IgA nephropathy; its selection as a featured late‑breaking oral presentation signals that the trial results meet the conference committee's bar for clinical relevance. The announcement confirms three ORIGIN‑related presentations: the primary ORIGIN 3 oral (Abstract TH‑OR083) and two informational posters for ORIGIN Extend and PIONEER scheduled during the conference.
The immediate business impact depends solely on the data content presented; the release does not disclose efficacy, safety, or statistical outcomes. Key dependencies include the actual numeric results, safety profile, and whether primary endpoints were met. Watch the plenary presentation on
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be delivered as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas, being held November 6 to 9. In addition, two informational posters will describe the ORIGIN Extend and PIONEER trials of atacicept in IgAN and other autoimmune mediated glomerular diseases.
ASN Kidney Week 2025 Presentation Details
| Title: | ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN |
| Presenting Author: | Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical Center |
| Abstract Number: | TH-OR083 |
| Session Title: | Opening Plenary: Featured High-Impact Clinical Trials |
| Session Date, Time: | Thursday, November 6, 2025 from 9:02 AM to 9:14 AM CST |
| Location: | Hall A, Convention Center |
| Title: | ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN |
| Presenting Author: | Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical Center |
| Poster Board Number: | INFO12-TH |
| Session Date, Time: | Thursday, November 6, 2025 from 10:00 AM to 12:00 PM CST |
| Location: | Exhibit Hall, Convention Center |
| Title: | PIONEER: A Basket Trial of Atacicept in Autoimmune Mediated Glomerular Disease |
| Presenting Author: | Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical Center |
| Poster Board Number: | INFO13-TH |
| Session Date, Time: | Thursday, November 6, 2025 from 10:00 AM to 12:00 PM CST |
| Location: | Exhibit Hall, Convention Center |
About Atacicept
Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated IgAN, lupus nephritis, and other autoimmune kidney diseases.
About the Atacicept Clinical Program
The ORIGIN Phase 2b clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further improvements in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN.
The ORIGIN Phase 3 trial met the primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria at week 36, in the prespecified interim analysis. Across the ORIGIN program in IgAN, the safety profile of atacicept appears favorable, and comparable to placebo.
Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA’s determination that, based on an assessment of data from the ORIGIN Phase 2b clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera Therapeutics believes atacicept is positioned for best-in-class potential, targeting B cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical trials across different disease areas.
The ORIGIN Extend study provides ORIGIN study participants with extended access to atacicept until its potential commercial availability in their region and captures longer-term safety and efficacy data. Atacicept is also being evaluated in expanded IgAN populations, anti-PLA2R positive primary membranous nephropathy, and anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) patients in the PIONEER trial.
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com.
Forward-looking Statements
Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the advancement, clinical development, regulatory milestones and commercialization of atacicept; the potential for atacicept to be best-in-class; and Vera Therapeutics’ plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “believe,” “plan,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
When will Vera Therapeutics (VERA) present ORIGIN Phase 3 atacicept data at ASN Kidney Week 2025?
Who is presenting Vera Therapeutics' ORIGIN 3 data (VERA) at ASN Kidney Week 2025?
What are the ASN Kidney Week 2025 poster details for Vera Therapeutics (VERA)?
What is the abstract number for Vera Therapeutics' ORIGIN 3 oral presentation (VERA)?
Where and when is ASN Kidney Week 2025 where Vera Therapeutics (VERA) will present?
